Life Settlement Assets PLC Reports Strong Final Results for 2025 with Improved Cash Position and Special Dividends

Life Settlement Assets PLC has delivered a pretty encouraging 2025 update. The headline message is simple enough: net asset value held up at USD 106.3 million, policy maturities came through at USD 20.6 million, the company says it finished the year in a strong cash position, and shareholders got both a special dividend and ongoing share buybacks.

That matters because LSA is not a typical investment trust. It invests in life settlement policies – existing life insurance policies bought from original holders – so returns depend heavily on policy maturities, cash collection and how accurately the portfolio is valued. This year’s RNS suggests the board is feeling more confident, especially about the HIV part of the portfolio.

Life Settlement Assets PLC final results 2025: the key numbers investors need

Metric	2025 result
Net asset value	USD 106.3 million
NAV per share	USD 2.41
Portfolio uplift	USD 8.0 million in HIV portfolio valuation
Total maturities declared	USD 20.6 million
Non-HIV maturities	USD 11.9 million
HIV maturities	USD 8.7 million
2025 special dividend	4.5307 cents per share, totalling USD 2.0 million
2025 buybacks	1,259,474 shares for USD 2.2 million
Post year-end special dividend	6.7960 US cents per share, totalling USD 3.0 million
Post year-end buybacks	415,954 shares for USD 0.7 million
Ongoing charges ratio	5.4% of average net assets

For retail investors, that is a solid set of operational markers. It shows cash is being realised from the portfolio and, crucially, some of it is being handed back to shareholders rather than just sitting on the balance sheet.

Net asset value and HIV portfolio uplift: why the USD 8.0 million change matters

The biggest valuation point in the release is the USD 8.0 million uplift in the HIV portfolio. This came from an update in the valuation model reflecting observed mortalities, which in plain English means the company used more real-world policy experience to refine what those assets are worth.

That is positive, but it is worth keeping your feet on the ground. This uplift is a valuation gain, not the same thing as cash in the bank on day one. It improves the reported value of the portfolio, yet investors should remember that model changes can flatter or hurt NAV depending on future experience.

Still, the chairman’s wording is notably upbeat. The board now takes a more optimistic view than it did during 2025 on future cash inflows from the portfolio as it shifts from non-HIV policies to an entirely HIV-based set of policies.

Policy maturities of USD 20.6 million show the Life Settlement Assets engine is still working

Maturities are the lifeblood of this sort of trust. In 2025, LSA declared maturities totalling USD 20.6 million, split between USD 11.9 million from non-HIV policies and USD 8.7 million from HIV policies.

That is important because it shows the portfolio is converting into real outcomes rather than just paper valuations. The chairman also said the company had positive actual-to-expected ratios across both policy segments, which suggests maturities were coming through at least as well as forecast.

LSA also said it ended the year in a strong cash position, although the exact cash figure was not disclosed in this RNS. For investors, that missing number is slightly frustrating, but the follow-on dividend and buyback activity does lend some weight to the board’s confidence.

MBC Action proceeds could add another 2026 catalyst for Life Settlement Assets

There is another moving part here: the Mutual Benefits Keep Policy Trust, or MBC, action. Administrative arrangements are nearing finalisation and the final proceeds are expected to be received during 2026.

This matters because extra proceeds could further support cash returns or strengthen the company’s balance sheet. The exact amount expected was not disclosed, so investors should treat this as a potential positive rather than money already in the bag.

Special dividends and share buybacks are a clear shareholder return story

LSA did not just talk about returns – it actually paid them. During 2025, the company declared a special dividend of 4.5307 cents per share, totalling USD 2.0 million, paid on 30 October 2025.

After the year end, it went again with a bigger special dividend of 6.7960 US cents per share, totalling USD 3.0 million, paid on 14 April 2026. Two special dividends in fairly quick succession tells you the board is comfortable enough with the cash position to release capital.

Buybacks also continued. In 2025 the company bought back and cancelled 1,259,474 shares, representing 2.8% of the issued share capital as at 31 December 2024, at a total cost of USD 2.2 million.

Since the year end it has bought back and cancelled a further 415,954 shares at a total cost of USD 0.7 million, equal to 0.9% of the issued share capital as at 31 December 2025. As at the report date, there were 43,727,515 shares in issue.

That combination of dividends and buybacks is hard to dislike. It gives shareholders direct cash today and can improve value per remaining share if buybacks are done at an attractive discount to underlying NAV, although the discount level was not disclosed in this announcement.

Costs are under control in cash terms, but the ongoing charges ratio has gone the wrong way

Now for the less flattering bit. LSA said total costs were marginally lower in 2025 despite inflationary pressures, which is a good operational sign.

However, the ongoing charges ratio rose from 5.0% to 5.4% of average net assets. Excluding policy servicing fees and legal costs, it also increased from 2.7% to 3.0%.

The company says that rise was due to the effect of share buybacks and dividends. That explanation makes sense mechanically because when net assets reduce, fixed costs can eat up a bigger percentage, but it is still not ideal. A 5.4% ongoing charges ratio is a number investors should watch closely, especially in a specialist trust where returns can already be lumpy.

Chairman outlook for 2026 points to more cash returns if conditions hold

Michael Baines struck a confident tone. He highlighted the three core priorities as accurate NAV forecasting, cost control and delivering returns to shareholders.

The standout comment was that the board will continue to explore opportunities to provide satisfactory returns through dividends and share repurchases. That is exactly what income-focused and discount-focused investors will want to hear.

The more optimistic stance on future cash inflows is also notable because it suggests management believes the portfolio transition is becoming easier to read. If that proves right, 2026 could be another year where realised cash, rather than just valuation discussion, drives the story.

What this Life Settlement Assets final results announcement means for retail investors

My view is that this is a positive update overall. The mix of an improved view on the HIV portfolio, USD 20.6 million of maturities, a strong cash position, and two special dividends makes this look like a business that is currently doing what shareholders need it to do.

The caution flags are not hard to spot either. Part of the good news comes from a model update rather than hard cash, the ongoing charges ratio is high and moving higher, and the size of the cash pile and the expected MBC proceeds were not disclosed here.

Even so, this RNS reads better than many specialist asset trust updates because it contains tangible shareholder returns, not just hopeful language. If LSA can keep maturities coming through, maintain cash discipline and avoid costs drifting further, the investment case looks firmer than it did a year ago.

In short, this was a good set of final results from Life Settlement Assets PLC. Not perfect, but definitely heading in the right direction.